Raymond James & Associates Immunity Bio, Inc. Transaction History
Raymond James & Associates
- $150 Billion
- Q2 2024
A detailed history of Raymond James & Associates transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 28,613 shares of IBRX stock, worth $94,995. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,613
Previous 23,413
22.21%
Holding current value
$94,995
Previous $125,000
44.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding IBRX
# of Institutions
216Shares Held
63.3MCall Options Held
1.43MPut Options Held
4.12M-
Vanguard Group Inc Valley Forge, PA13.8MShares$45.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$37.9 Million0.0% of portfolio
-
State Street Corp Boston, MA7.86MShares$26.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.92MShares$13 Million0.0% of portfolio
-
Jane Street Group, LLC New York, NY1.72MShares$5.7 Million0.01% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.33B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...